Drug Profile


Alternative Names: CKD-943; CR 845; FE 202845; MR13A9

Latest Information Update: 08 Nov 2016

Price : $50

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Cara Therapeutics; Chong Kun Dang; Maruishi Pharmaceutical
  • Class Opioid analgesics; Peptides
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Postoperative pain
  • Phase II/III Pruritus
  • Phase II Pain

Most Recent Events

  • 01 Oct 2016 Cara Therapeutics initiates enrolment in a pharmacokinetic safety phase I trial in uraemic Pruritus
  • 15 Sep 2016 Cara Therapeutics initiates enrolment in a phase IIb trial for Chronic pain in USA
  • 05 Aug 2016 Cara Therapeutics plans to initiate a pharmacokinetic safety trial in uraemic Pruritus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top